Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherAccelerated Communication

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

Brian W. Ogilvie, Donglu Zhang, Wenying Li, A. David Rodrigues, Amy E. Gipson, Jeff Holsapple, Paul Toren and Andrew Parkinson
Drug Metabolism and Disposition January 2006, 34 (1) 191-197; DOI: https://doi.org/10.1124/dmd.105.007633
Brian W. Ogilvie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donglu Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenying Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. David Rodrigues
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy E. Gipson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Holsapple
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Toren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Parkinson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 34 no. 1 191-197
DOI 
https://doi.org/10.1124/dmd.105.007633
PubMed 
16299161

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received October 11, 2005
  • Accepted November 15, 2005
  • Published online December 20, 2005.

Article Versions

  • Earlier version (November 18, 2005 - 10:20).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Brian W. Ogilvie,
  2. Donglu Zhang,
  3. Wenying Li,
  4. A. David Rodrigues,
  5. Amy E. Gipson,
  6. Jeff Holsapple,
  7. Paul Toren and
  8. Andrew Parkinson
  1. XenoTech, LLC, Lenexa, Kansas (B.W.O., A.E.G., J.H., P.T., A.P.); and Pharmaceutical Candidate Optimization (D.Z., W.L., A.D.R.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey
  1. Address correspondence to:
    Dr. Andrew Parkinson, XenoTech, LLC, 16825 West 116th Street, Lenexa, KS 66219. Email: aparkinson{at}xenotechllc.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: November 2005 to June 2022

AbstractFullPdf
Nov 2005480221
Dec 200514040397
Jan 20069893182
Feb 2006586492
Mar 2006764765
Apr 2006334564
May 2006255355
Jun 2006273645
Jul 2006252739
Aug 2006231316
Sep 2006163226
Oct 2006311727
Nov 2006434046
Dec 2006181922
Jan 2007255758
Feb 20072316137
Mar 2007177158
Apr 2007365452
May 2007264357
Jun 2007273938
Jul 2007283850
Aug 2007253544
Sep 2007234037
Oct 2007345650
Nov 2007265361
Dec 2007143636
Jan 2008164055
Feb 2008169354
Mar 2008143232
Apr 2008204257
May 2008335158
Jun 2008203142
Jul 2008386553
Aug 2008425038
Sep 2008414137
Oct 2008396765
Nov 2008424644
Dec 2008202125
Jan 2009283138
Feb 2009203644
Mar 2009264239
Apr 2009264849
May 2009312648
Jun 2009333843
Jul 2009334446
Aug 2009424641
Sep 2009363852
Oct 2009324889
Nov 2009423259
Dec 2009371629
Jan 2010473029
Feb 2010522224
Mar 2010765858
Apr 2010512020
May 2010613137
Jun 2010443450
Jul 2010502939
Aug 2010374424
Sep 2010604640
Oct 2010635233
Nov 2010424128
Dec 2010363021
Jan 2011403224
Feb 2011595144
Mar 2011616144
Apr 2011474240
May 2011556356
Jun 2011764847
Jul 2011464637
Aug 2011585932
Sep 2011548346
Oct 2011618846
Nov 2011828247
Dec 2011493242
Jan 2012485035
Feb 2012496655
Mar 2012533528
Apr 2012476941
May 2012485541
Jun 2012526144
Jul 2012695753
Aug 2012416833
Sep 20126210434
Oct 2012494461
Nov 2012417744
Dec 2012395229
Jan 2013839246
Feb 2013607231
Mar 2013667237
Apr 2013718037
May 2013605734
Jun 2013414340
Jul 2013433726
Aug 2013253325
Sep 2013564827
Oct 2013415820
Nov 2013243722
Dec 2013163720
Jan 2014334334
Feb 2014384339
Mar 2014525635
Apr 2014638259
May 2014366330
Jun 2014344824
Jul 2014473935
Aug 2014356231
Sep 2014406972
Oct 2014413733
Nov 2014236432
Dec 2014196125
Jan 2015385133
Feb 2015163921
Mar 2015334537
Apr 2015295222
May 2015206525
Jun 2015234123
Jul 2015344728
Aug 2015204720
Sep 2015346133
Oct 2015176932
Nov 2015254841
Dec 2015203011
Jan 2016304635
Feb 2016354536
Mar 2016374946
Apr 2016255329
May 2016303119
Jun 2016304654
Jul 2016193514
Aug 2016464029
Sep 2016204623
Oct 2016195125
Nov 2016255822
Dec 201656113
Jan 2017811630
Feb 2017119020
Mar 20171413537
Apr 201788820
May 201755429
Jun 201714026
Jul 201793723
Aug 201737723
Sep 201787124
Oct 2017410430
Nov 2017119114
Dec 201735112
Jan 201855514
Feb 2018115928
Mar 201847222
Apr 201857330
May 2018115323
Jun 201827225
Jul 2018010929
Aug 201804218
Sep 201804226
Oct 201865216
Nov 201857113
Dec 2018571412
Jan 2019671014
Feb 2019441116
Mar 2019391932
Apr 2019531816
May 2019351611
Jun 2019241020
Jul 2019311316
Aug 2019551610
Sep 2019502119
Oct 2019401015
Nov 2019832013
Dec 2019491811
Jan 2020291814
Feb 202036165
Mar 2020242115
Apr 2020481616
May 2020452228
Jun 2020391911
Jul 20205685
Aug 20203854
Sep 2020501912
Oct 20203586
Nov 2020341810
Dec 2020352510
Jan 202133523
Feb 2021446810
Mar 202163176
Apr 20212793
May 202132228
Jun 202141436
Jul 2021302414
Aug 202138454
Sep 202135279
Oct 202132153
Nov 202174115
Dec 202153174
Jan 202250148
Feb 2022421410
Mar 20225871
Apr 202273168
May 2022601411
Jun 202242118

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (1)
Drug Metabolism and Disposition
Vol. 34, Issue 1
1 Jan 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherAccelerated Communication

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

Brian W. Ogilvie, Donglu Zhang, Wenying Li, A. David Rodrigues, Amy E. Gipson, Jeff Holsapple, Paul Toren and Andrew Parkinson
Drug Metabolism and Disposition January 1, 2006, 34 (1) 191-197; DOI: https://doi.org/10.1124/dmd.105.007633

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherAccelerated Communication

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

Brian W. Ogilvie, Donglu Zhang, Wenying Li, A. David Rodrigues, Amy E. Gipson, Jeff Holsapple, Paul Toren and Andrew Parkinson
Drug Metabolism and Disposition January 1, 2006, 34 (1) 191-197; DOI: https://doi.org/10.1124/dmd.105.007633
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Use of CYP Transgenic Mouse Models
  • Nonlinear Metabolite Kinetics of Verapamil
  • Production of Recombinant hsa-mir-27b
Show more ACCELERATED COMMUNICATIONS

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics